01 July 2006
Outcome and prognosis of severe thrombotic microangiopathies treated by plasmaexchange.
Laure Federici, Kada Klouche, Laurent Amigues, Tarik Kanouni, Ernesto Lopez-Martinez, Pascal Latry, Jean Jacques Beraud, Jean Francois RossiMed Sci Monit 2006; 12(7): CR302-307 :: ID: 452202
Abstract
Background: Plasma exchange (PE) therapy has dramatically improved theoutcome of thrombotic microangiopathies (TMA) in adults. However, resistance to PE, which indicates apoor prognosis, is observed in 1/3 of patients and remains not fully understood. We evaluated in thisstudy the survival and the long-term outcome of severe TMA treated by PE and identified the predictivefactors of resistance to PE and of mortality. Material/Methods: Records of adults with severe TMA treatedby PE were reviewed. Clinical and biological data, therapeutic delay to PE, plasma volume exchange perprocedure, and number of PE sessions were collected. Mortality was assessed at one month and at one-yearfollow-up. All data were analyzed and compared between survived/deceased and between responder/non-responderpatients. Results: Nineteen females and six males were included. Mean age (+/-SD) was 46.8+/-16.3 years,Glasgow coma score 11+/-3, and Sequential Organ Failure Assessment (SOFA) score 5.8+/-2.8. Nineteen patientspartially or fully responded to PE. Twenty patients were alive at one month and 19 at one year. The responseto PE was the single discriminating parameter between survivors and non-survivors. A longer delay ofPE and a neoplastic cause of TMA were significantly higher in the non-responders. Conclusions: SevereTMA treated by PE had a fair prognosis, with a survival rate at 76% after one year of follow-up. Unresponsivenessto PE was the only predictive factor of mortality; a neoplastic etiology of TMA and a longer therapeuticdelay of PE were predictive of resistance to PE.
Keywords: Plasma Exchange, Thrombosis - therapy, Vascular Diseases - therapy
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
18 Mar 2024 : Clinical Research
Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative StudyMed Sci Monit In Press; DOI: 10.12659/MSM.944136
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
Most Viewed Current Articles
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952